20:09 , Mar 1, 2019 |  BC Week In Review  |  Company News

Clementia takeout to bolster Ipsen’s orphan pipeline

Ipsen Group (Euronext:IPN; Pink:IPSEY) will broaden its rare disease pipeline by acquiring Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) for $1 billion up front. At $25 per share, the deal price is a 67% premium to Clementia's close...
23:11 , Feb 25, 2019 |  BC Extra  |  Company News

Clementia takeout to bolster Ipsen’s orphan pipeline

Ipsen Group (Euronext:IPN; Pink:IPSEY) will broaden its rare disease pipeline by acquiring Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) for $1 billion up front. At $25 per share, the deal price is a 67% premium to Clementia's close...
23:50 , Jul 27, 2017 |  BC Week In Review  |  Clinical News

FDA approves Triptodur for central precocious puberty

Debiopharm Group (Lausanne, Switzerland) and Arbor Pharmaceuticals LLC (Atlanta, Ga.) said FDA approved Triptodur triptorelin to treat pediatric patients ages ≥2 with central precocious puberty. The companies plan to launch the product in 4Q17. Triptodur...
00:28 , Mar 31, 2017 |  BC Innovations  |  Targets & Mechanisms

Cells on the rise

This year’s meeting of the American Association for Cancer Research (AACR) will keep the spotlight on immuno-oncology, where preclinical science is continuing to expand the use of different types of innate and adaptive immune cells...
21:37 , Mar 22, 2017 |  BC Week In Review  |  Clinical News

Decapeptyl regulatory update

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) approved a label expansion for Decapeptyl triptorelin pamoate to include its use as an adjuvant in combination with tamoxifen or an aromatase inhibitor to treat endocrine-responsive,...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Company News

Primm Pharma, Xbrane deal

Xbrane acquired Primm Pharma for an undisclosed sum. Xbrane gains Primm’s portfolio of five peptide-based generics using the company’s microsphere slow-release formulation. Xbrane hopes to launch Spherotide early next year in “less regulated markets” following...
07:00 , Jul 20, 2015 |  BC Week In Review  |  Clinical News

Triptorelin pamoate: Phase III data

An open-label, international Phase III trial in 44 patients with CPP showed that 2 intramuscular injections of a 6-month formulation of 22.5 mg triptorelin pamoate over 12 months led to >93% of patients with prepubertal...
08:00 , Dec 22, 2014 |  BC Week In Review  |  Company News

Actavis, Debiopharm sales and marketing update

Actavis’ Actavis Specialty Pharmaceuticals Co. subsidiary and Debiopharm launched a six-month dosing option of 22.5 mg Trelstar triptorelin pamoate in Canada to treat hormone-dependent advanced prostate cancer. Actavis has U.S. and Canadian rights to the...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Clinical News

Decapeptyl triptorelin pamoate: Additional Phase III data

Additional data from a single-arm, open-label, European Phase III trial in patients with locally advanced or metastatic prostate cancer showed that a 3-month formulation of 11.25 mg subcutaneous Decapeptyl led to castration in 97.6% of...
07:00 , Jun 9, 2014 |  BC Week In Review  |  Company News

Debiopharm, Orient EuroPharma Co. Ltd. deal

Debiopharm granted Orient EuroPharma exclusive commercialization rights to Pamorelin LA in Singapore and undisclosed countries in Southeast Asia. The partners also said Orient EuroPharma subsequently launched the product in Singapore to treat locally advanced or...